Middle East & Africa Dermatology OTC Medications Market Share by Size and Growth 2028

The MEA dermatology OTC medications market is expected to grow from US$ 666.64 million in 2021 to US$ 792.34 million by 2028; it is estimated to grow at a CAGR of 2.5% from 2021 to 2028.

One of the dermatology OTC medications market's most visible trends is the shift of manufacturers from prescription pharmaceuticals toward over-the-counter products. Many manufacturers are shifting their products from Rx (prescription) to OTC. In its 2019 annual report, Bayer AG declared it would convert some of its prescriptive medications suitable for self-care to OTC as part of its strategy. This strategy is expected to increase the availability of OTC medications for a variety of illnesses in developing and developed countries. Rx-to-OTC is a feasible and enticing alternative for organizations seeking a life cycle extension strategy, enabling consumers to take control of their health. Transitioning to an OTC model may assist in maintaining target revenue and increasing a product's lifetime value. Furthermore, organizations with pharmaceutical and consumer health sections can readily implement the Rx-to-OTC approach. Moreover, Rx-to-OTC conversions offer significant benefits to patients, retailers, and manufacturers. Patients including the unique benefits of OTC drugs, such as lower costs and the opportunity to make treatment decisions without the involvement of doctors or insurers. Retailers gain from having more selections on their shelves, especially if the product is well known. As people spend more money on OTC products than on prescription drugs, there will be a tremendous need for OTC products in the future years.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA dermatology OTC medications market. The MEA dermatology OTC medications market is expected to grow at a good CAGR during the forecast period.

MEA Dermatology OTC Medications Market Revenue and Forecast to 2028 (US$ Million)

MEA Dermatology OTC Medications Market Segmentation

The MEA dermatology OTC medications market is segmented intoproduct type, route of administration, indication, distribution channel, and country. Based on product type, the market is segmented into tablets and capsules, gels, creams and ointments, and others. The creams and ointments segment dominated the market in 2020; however, the tablets and capsules segment is expected to be the fastest growing segment during the forecast period. Based on route of administration, the market is segmented into topical and oral. The topical segment dominated the market in 2020; however, the oral segment is expected to be a faster growing segment during the forecast period. Based on indication, the market is segmented into dermatitis, acne, psoriasis, skin bleaching, fungal disease, warts, and others. The acne segment dominated the market in 2020 and is expected to be the fastest growing segment during the forecast period. The dermatitis segment is further classified into atopic dermatitis, contact dermatitis, and others. The acne segment is also segmented into non-inflammatory acne and inflammatory acne. The psoriasis segment is segmented into plaque psoriasis, guttate psoriasis, and others. The fungal disease is further segmented into athlete's foot, ringworm, fungal nail infections, and others. Moreover, the warts segment is further segmented into common warts, flat warts, and others. Based on distribution channel, the market is segmented into online distribution and offline distribution. The offline distribution segment dominated the market in 2020; however, the online distribution segment is expected to be a faster growing segment during the forecast period. The offline distribution is further segmented into retail and hospital pharmacies and super and hypermarkets. Based on country, the market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of the MEA.

Bausch Health Companies Inc.; Bayer AG; Dr. Reddy's Laboratories; Galderma; GlaxoSmithKline plc.; Johnson and Johnson Services, Inc.; LEO Pharma A/S; Perrigo Company plc; and Viatris Inc. are among the leading companies in the MEA dermatology OTC medications market.

Middle East & Africa Dermatology OTC Medications Market Strategic Insights

Get more information on this report

Middle East & Africa Dermatology OTC Medications Market Segmentation Analysis

Middle East & Africa Dermatology OTC Medications Market Report Highlights

Middle East & Africa Dermatology OTC Medications Report Scope

Report Attribute	Details
Market size in 2021	US$ 666.64 Million
Market Size by 2028	US$ 792.34 Million
CAGR (2021 - 2028)	2.5%
Historical Data	2019-2020
Forecast period	2022-2028
Segments Covered	By Product Type Tablets and Capsules Gels Creams Ointments By Route of Administration Topical Oral By Indication Dermatitis Acne Psoriasis Skin Bleaching Fungal Disease Warts By Distribution Channel Online Distribution Offline Distribution
Regions and Countries Covered	Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Bausch Health Companies Inc. Bayer AG Dr. Reddy's Laboratories Galderma GlaxoSmithKline plc. Johnson and Johnson Services, Inc. LEO Pharma A/S Perrigo Company plc Viatris Inc.